Imagine a future where the onset of Alzheimer’s or Parkinson’s disease could be predicted and effectively treated before symptoms even appear. Neurodegenerative diseases have long remained shrouded in a veil of uncertainty, with definitive diagnoses often coming too late to alter their devastating trajectories. Biomarkers are the beacons of hope in this landscape, potentially revolutionizing…
Showcasing Pioneering Diagnostic Technologies We proudly announce that Neurodex will play a significant role at the forthcoming Bio-Neuroscience Conference, highlighting our innovative diagnostic technologies for neurodegenerative diseases. Oded Biran, our distinguished SEO, will present our leading-edge work in developing blood-based biomarkers and leveraging cell-specific extracellular vesicles (exosomes) for precise diagnostics. About Our Innovations Neurodex is…
Introduction: The global Neurodegenerative Disease Market is on the cusp of significant expansion, driven by the rising prevalence of neurodegenerative diseases such as Parkinson’s, multiple sclerosis, and Alzheimer’s disease. According to a recent study by MarketDigits, the market is projected to reach USD 69.8 billion by 2030, growing at a robust CAGR of 6.2% during…
Introduction Leqembi® Arrives in China for Alzheimer’s Care Eisai, in partnership with BioArctic AB, has announced China’s approval of Leqembi® (乐意保), a groundbreaking treatment for mild cognitive impairment and mild dementia in Alzheimer’s disease. Following its success in the United States and Japan, this approval marks a significant stride in global healthcare. Understanding Alzheimer’s and…
Introduction Once thought to be mere cellular debris, exosomes have emerged as significant players in neurodegenerative diseases. These extracellular vesicles, ranging from 30 to 100 nm in size, are produced by all cell types in the central nervous system (CNS). Far from being simple waste disposal units, exosomes are involved in complex intercellular communication and…
NATICK, MA, USA, October 31, 2023 /EINPresswire.com/ — NeuroDex, Inc. (“NeuroDex”, or the “Company”), announces that it has received a second grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), to study “Neuronal extracellular vesicles blood-based biomarker for lysosomal function.” This award will enable NeuroDex to utilize its unique ExoSORT™ platform to develop an…
Introduction: Neurodex is pleased to announce its participation in the upcoming 2nd Annual Meeting hosted by the American Association of Extracellular Vesicles (AAEV). Set against the picturesque backdrop of Boston, MA, this event promises to gather esteemed experts in extracellular vesicle research. Neurodex is gearing up to share its latest insights into the study of…
In a remarkable stride towards advancing healthcare, Canadian innovators have unveiled a groundbreaking artificial intelligence (AI) program to transform the early detection of Amyotrophic Lateral Sclerosis (ALS). Mitsubishi Tanabe Pharma Canada (MTP-CA) takes immense pride in supporting this revolutionary AI technology, which harnesses the power of AI to scrutinize de-identified electronic medical records (EMRs). This…
Cambridge, MA & Singapore, August 09, 2023 Sunbird Bio, a pioneering biotechnology company focused on advancing the diagnosis and treatment of neurological disorders and early-stage cancer through proprietary protein-based technologies, has successfully merged with Glympse Bio. The merger aims to expedite the development of the two companies protein-based diagnostic platforms, creating a powerful entity named…
Roche, a leading biotechnology company, has obtained clearance from the U.S. Food and Drug Administration (FDA) for other Alzheimer’s disease Cerebrospinal Fluid (CSF) assays. The newly cleared assays, known as Elecsys tTau/Abeta42 ratio, are crucial in enabling timely diagnosis and facilitating treatment decisions for Alzheimer’s disease. The Elecsys tTau/Abeta42 ratio is designed to assist clinicians…